PubMed Health⌕ Search

PubMed · 12780100

Long-lived planetary vortices and their evolution: Conservative intermediate geostrophic model.

Abstract

Large, long-lived vortices, surviving during many turnaround times and far longer than the dispersive linear Rossby wave packets, are abundant in planetary atmospheres and oceans. Nonlinear effects which prevent dispersive decay of intense cyclones and anticyclones and provide their self-propelling propagation are revised here using shallow water equations and their balanced approximations. The main physical mechanism allowing vortical structures to be long-lived in planetary fluid is the quick fluid rotation inside their cores which prevents growth in the amplitude of asymmetric circulation arising due to the beta-effect. Intense vortices of both signs survive essentially longer than the linear Rossby wave packet if their azimuthal velocity is much larger than the Rossby wave speed. However, in the long-time evolution, cyclonic and anticyclonic vortices behave essentially differently that is illustrated by the conservative intermediate geostrophic model. Asymmetric circulation governing vortex propagation is described by the azimuthal mode m=1 for the initial value problem as well as for steadily propagating solutions. Cyclonic vortices move west-poleward decaying gradually due to Rossby wave radiation while anticyclonic ones adjust to non-radiating solitary vortices. Slow weakening of an intense cyclone with decreasing of its size and shrinking of the core is described assuming zero azimuthal velocity outside the core while drifting poleward. The poleward tendency of the cyclone motion relative to the stirring flow corresponds to characteristic trajectories of tropical cyclones in the Earth's atmosphere. The asymmetry in dispersion-nonlinear properties of cyclones and anticyclones is thought to be one of the essential reasons for the observed predominance of anticyclones among long-lived vortices in the atmospheres of the giant planets and also among intrathermoclinic eddies in the ocean.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Georgi G. Sutyrin. 1994. Long-lived planetary vortices and their evolution: Conservative intermediate geostrophic model.. https://doi.org/10.1063/1.166004

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗